.Pharmacolibrary.Drugs.ATC.L.L04AF04

Information

name:Filgotinib
ATC code:L04AF04
route:oral
n-compartments2

Filgotinib is an oral, selective Janus kinase 1 (JAK1) inhibitor indicated for the treatment of moderate-to-severe rheumatoid arthritis and moderately to severely active ulcerative colitis. It is approved for use in several regions, including Europe and Japan.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult subjects, after single-dose oral administration.

References

  1. Westhovens, R (2023). Filgotinib in rheumatoid arthritis. Expert review of clinical immunology 19(2) 135–144. DOI:10.1080/1744666X.2023.2149495 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36396615

  2. Meng, A, et al., & Mathias, A (2022). Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies. British journal of clinical pharmacology 88(7) 3211–3221. DOI:10.1111/bcp.15239 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35072287

Revisions

Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos